This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mohan, R. R. Articles by Mukhtar, H. Search for Related Content PubMed PubMed Citation Articles by Mohan, R. R. Articles by Mukhtar, H.

Overexpression of Ornithine Decarboxylase in Prostate Cancer and Prostatic Fluid in Humans¹

Departments of Dermatology [R. R. M., A. C., S. G., N. A., R. A., H. M.], Urology [S. R. M., M. I. R.], Epidemiology and Biostatistics [S. B. A.], and Pathology [F. P., G. T. M.], Case Western Reserve University, Cleveland, Ohio 44106, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905 [D. G. B.]

Prostate cancer (PCA), the most commonly diagnosed cancer in males in the United States, is the second leading cause of cancer-related deaths of males in this country. Because of the poor success rate in the treatment of PCA, an intervention at an early stage may reduce the progression of small carcinoma to large metastatic lesion, thereby reducing PCA-related deaths. Concerted efforts are needed to establish mechanism-based approaches to develop: (a) the markers for early detection of the disease as well as toward monitoring the efficacy of treatment(s); and (b) novel chemopreventive strategies against PCA. Using unique samples of pair-matched benign and cancer tissue obtained from the same PCA patient, we showed that ornithine decarboxylase (ODC) activity is significantly (P < 0.001) elevated in PCA (1142 ± 100; mean ± SE) than in paired benign tissue (427 ± 51; mean ± SE). The immunoblot analysis also showed a significant elevation in the protein expression of ODC in the PCA tissues as compared with the paired benign tissue. Furthermore, our data showed that the ODC activity in the prostatic fluid obtained by a digital rectal massage from the patients with PCA (3847 ± 162; mean ± SE) was significantly higher than in the patients with benign prostatic hyperplasia (2742 ± 167; mean ± SE) or normal individuals (1244 ± 67; mean ± SE). This observation might be of significance because the prostatic fluid could be obtained noninvasively by digital rectal massage. We suggest that ODC could serve as a target for early detection of human PCA as well as for monitoring the efficacy of treatment(s). The development of ODC as a target for novel chemopreventive strategies against PCA is an intriguing possibility.

This article has been cited by other articles:

				L. R. Saunders and E. Verdin Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol. Cancer Ther., November 1, 2006; 5(11): 2777 - 2785. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				C. A. Hobbs, G. Wei, K. DeFeo, B. Paul, C. S. Hayes, and S. K. Gilmour Tip60 Protein Isoforms and Altered Function in Skin and Tumors that Overexpress Ornithine Decarboxylase Cancer Res., August 15, 2006; 66(16): 8116 - 8122. [Abstract] [Full Text] [PDF]

				L. Young, R. Salomon, W. Au, C. Allan, P. Russell, and Q. Dong Ornithine Decarboxylase (ODC) Expression Pattern in Human Prostate Tissues and ODC Transgenic Mice J. Histochem. Cytochem., February 1, 2006; 54(2): 223 - 229. [Abstract] [Full Text] [PDF]

				P. Nummela, M. Yin, M. Kielosto, V. Leaner, M. J. Birrer, and E. Holtta Thymosin {beta}4 Is a Determinant of the Transformed Phenotype and Invasiveness of S-Adenosylmethionine Decarboxylase-Transfected Fibroblasts Cancer Res., January 15, 2006; 66(2): 701 - 712. [Abstract] [Full Text] [PDF]

				V. A. Levin, J. L. Jochec, L. M. Shantz, P. E. Koch, and A. E. Pegg Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to Difluoromethylornithine J. Histochem. Cytochem., November 1, 2004; 52(11): 1467 - 1474. [Abstract] [Full Text] [PDF]

				C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403. [Abstract] [Full Text] [PDF]

				V. A. Levin, K. R. Hess, A. Choucair, P. J. Flynn, K. A. Jaeckle, A. P. Kyritsis, W. K. A. Yung, M. D. Prados, J. M. Bruner, S. Ictech, et al. Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination {alpha}-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas Clin. Cancer Res., March 1, 2003; 9(3): 981 - 990. [Abstract] [Full Text] [PDF]

				J. K. Park, Y. M. Chung, S. Kang, J.-U. Kim, Y.-T. Kim, H. J. Kim, Y. H. Kim, J. S. Kim, and Y. D. Yoo c-Myc Exerts a Protective Function through Ornithine Decarboxylase against Cellular Insults Mol. Pharmacol., December 1, 2002; 62(6): 1400 - 1408. [Abstract] [Full Text] [PDF]

				R. G. Schipper and A. A.J. Verhofstad Distribution Patterns of Ornithine Decarboxylase in Cells and Tissues: Facts, Problems, and Postulates J. Histochem. Cytochem., September 1, 2002; 50(9): 1143 - 1160. [Abstract] [Full Text] [PDF]

				A. R. Simoneau, E. W. Gerner, M. Phung, C. E. McLaren, and F. L. Meyskens Jr. {{alpha}}-Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial J Natl Cancer Inst, January 3, 2001; 93(1): 57 - 59. [Full Text] [PDF]

				S. Gupta, N. Ahmad, S. R. Marengo, G. T. MacLennan, N. M. Greenberg, and H. Mukhtar Chemoprevention of Prostate Carcinogenesis by {{alpha}}-Difluoromethylornithine in TRAMP Mice Cancer Res., September 1, 2000; 60(18): 5125 - 5133. [Abstract] [Full Text]

				B. Saverio, D. Pierpaola, A. Serenella, C. Cesare, M. Bruno, T. Auro, and C. Arnaldo Tumor Progression Is Accompanied by Significant Changes in the Levels of Expression of Polyamine Metabolism Regulatory Genes and Clusterin (Sulfated Glycoprotein 2) in Human Prostate Cancer Specimens Cancer Res., January 1, 2000; 60(1): 28 - 34. [Abstract] [Full Text]

				S. Gupta, N. Ahmad, R. R. Mohan, M. M. Husain, and H. Mukhtar Prostate Cancer Chemoprevention by Green Tea: In Vitro and in Vivo Inhibition of Testosterone-mediated Induction of Ornithine Decarboxylase Cancer Res., May 1, 1999; 59(9): 2115 - 2120. [Abstract] [Full Text] [PDF]